{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:33Z","timestamp":1707524433377},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,13]]},"DOI":"10.7759\/cureus.19549","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T04:01:29Z","timestamp":1636862489000},"source":"Crossref","is-referenced-by-count":0,"title":["Duration of Dual Antiplatelet Therapy After Stent Implantation, Still an Enigma: A Systematic Review of Randomized Clinical Trials"],"prefix":"10.7759","author":[{"given":"Muhammad Bin","family":"Aslam Zahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marrium S","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamatha","family":"Tappiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignarth","family":"Shantha Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armaan M","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavya","family":"Koganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihan A","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Centers for Disease Control and Prevention. About underlying cause of death, 1999-2019. (2018). Accessed: August 12, 2021: https:\/\/wonder.cdc.gov\/ucd-icd10.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin EJ","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, et al.. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019, 139:e56-e528. 10.1161\/CIR.0000000000000659","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon MB","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, et al.. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998, 339:1665-71. 10.1056\/NEJM199812033392303","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000651","article-title":"Dual antiplatelet therapy for secondary prevention of coronary artery disease","volume":"4","author":"Degrauwe S","year":"2017","unstructured":"Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Ope Hea. 2017, 4:e000651. 10.1136\/openhrt-2017-000651","journal-title":"Ope Hea"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based\u00a0on ischemic and bleeding risks after coronary\u00a0stenting","volume":"73","author":"Costa F","year":"2019","unstructured":"Costa F, Van Klaveren D, Feres F, et al.. Dual antiplatelet therapy duration based\u00a0on ischemic and bleeding risks after coronary\u00a0stenting. J Am Coll Cardiol. 2019, 73:741-54. 10.1016\/j.jacc.2018.11.048","journal-title":"J Am Coll Cardiol"},{"key":"ref6","unstructured":"American Heart Association. What is dual antiplatelet therapy (DAPT)?. (2017). Accessed: August 15,\u00a0 2021: https:\/\/www.heart.org\/-\/media\/files\/health-topics\/answers-by-heart\/what-is-dapt.pdf."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31823ba622","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions","volume":"124","author":"Levine GN","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC, et al.. 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2011, 124:e574-e651. 10.1161\/CIR.0b013e31823ba622","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann FJ","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, et al.. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019, 40:87-165. 10.1093\/eurheartj\/ehy394","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli M","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al.. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018, 39:213-60. 10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174502","article-title":"Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT duration","volume":"12","author":"Toyota T","year":"2017","unstructured":"Toyota T, Shiomi H, Morimoto T, Natsuaki M, Kimura T. Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a comparison between the DAPT study and 9 other trials evaluating DAPT duration. PLoS One. 2017, 12:e0174502. 10.1371\/journal.pone.0174502","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh RW","year":"2015","unstructured":"Yeh RW, Kereiakes DJ, Steg PG, et al.. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015, 65:2211-21. 10.1016\/j.jacc.2015.03.003","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn JY","year":"2018","unstructured":"Hahn JY, Song YB, Oh JH, et al.. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018, 391:1274-1284. 10.1016\/S0140-6736(18)30493-8","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial","volume":"9","author":"Han Y","year":"2016","unstructured":"Han Y, Xu B, Xu K, et al.. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv. 2016, 9:10.1161\/CIRCINTERVENTIONS.115.003145","journal-title":"Circ Cardiovasc Interv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv481","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft G","year":"2016","unstructured":"Helft G, Steg PG, Le Feuvre C, et al.. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016, 37:365-74. 10.1093\/eurheartj\/ehv481","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18\u00a0months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura M","year":"2017","unstructured":"Nakamura M, Iijima R, Ako J, et al.. Dual antiplatelet therapy for 6 versus 18\u00a0months after biodegradable polymer drug-eluting stent implantation. JACC Cardiovasc Interv. 2017, 10:1189-98. 10.1016\/j.jcin.2017.04.019","journal-title":"JACC Cardiovasc Interv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke S","year":"2015","unstructured":"Schulz-Sch\u00fcpke S, Byrne RA, Ten Berg JM, et al.. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015, 36:1252-63. 10.1093\/eurheartj\/ehu523","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.03.049","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting\u00a0stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for DES after discontinuation of Clopidogrel)","volume":"10","author":"Didier R","year":"2017","unstructured":"Didier R, Morice MC, Barragan P, et al.. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting\u00a0stents in patients nonresistant to aspirin: final results of the ITALIC trial (is there a life for DES after discontinuation of Clopidogrel). JACC Cardiovasc Interv. 2017, 10:1202-10. 10.1016\/j.jcin.2017.03.049","journal-title":"JACC Cardiovasc Interv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi E","year":"2018","unstructured":"Kedhi E, Fabris E, van der Ent M, et al.. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018, 363:k3793. 10.1136\/bmj.k3793","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by Clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe H","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, et al.. Effect of 1-month dual antiplatelet therapy followed by Clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA. 2019, 321:2414-27. 10.1001\/jama.2019.8145","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2015.10.001","article-title":"Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents","volume":"9","author":"Hermiller JB","year":"2016","unstructured":"Hermiller JB, Krucoff MW, Kereiakes DJ, et al.. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv. 2016, 9:138-47. 10.1016\/j.jcin.2015.10.001","journal-title":"JACC Cardiovasc Interv"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following\u00a0long\u00a0everolimus-eluting stent\u00a0implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"Hong SJ","year":"2016","unstructured":"Hong SJ, Shin DH, Kim JS, et al.. 6-month versus 12-month dual-antiplatelet therapy following\u00a0long\u00a0everolimus-eluting stent\u00a0implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv. 2016, 9:1438-46. 10.1016\/j.jcin.2016.04.036","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/72264-duration-of-dual-antiplatelet-therapy-after-stent-implantation-still-an-enigma-a-systematic-review-of-randomized-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:33Z","timestamp":1707507393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/72264-duration-of-dual-antiplatelet-therapy-after-stent-implantation-still-an-enigma-a-systematic-review-of-randomized-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.19549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,13]]}}}